

FAX FORM TO: 1.866.233.8317

PHONE: 1.855.492.0817

EMAIL: [contact@bluegrass-rx.com](mailto:contact@bluegrass-rx.com)

Complete the following or include demographic sheet.

1. PATIENT INFORMATION		2. PRESCRIBER INFORMATION	
Name: _____		Name: _____	
Address: _____		DEA #: _____	NPI #: _____ State Lic. #: _____
City, State, ZIP: _____		Group or Hospital: _____	
Primary Phone: - -	DOB: / /	Address: _____	
Alternate Phone: - -	Gender: _____	City, State, Zip: _____	
Email: _____		Phone: - -	Fax: - -
Primary Language: _____	Last Four of SSN: _____	Contact Person: _____ Phone: - -	

3. INSURANCE INFORMATION		<i>Fax copy of prescription and insurance cards with this form, if available (front and back)</i>	
Primary Insurance Company Name: _____		Secondary Insurance Company Name: _____	
Primary Cardholder Name: _____		Secondary Cardholder Name: _____	
Relationship: <input type="radio"/> Self <input type="radio"/> Spouse/Partner <input type="radio"/> Child/Dependent	Relationship: <input type="radio"/> Self <input type="radio"/> Spouse/Partner <input type="radio"/> Child/Dependent		
Phone: - - Member ID: _____ Group #: _____	Phone: - - Member ID: _____ Group #: _____		

4. DIAGNOSIS AND CLINICAL INFORMATION	
Needs by Date: / /	Ship to: <input type="radio"/> Patient <input type="radio"/> Office <input type="radio"/> Other:
<b>ICD-10 Code</b>	<b>Patient Evaluation</b>
<input type="radio"/> P07.21 <23 weeks of gestation <input type="radio"/> P07.22 23 weeks of gestation <input type="radio"/> P07.23 24 weeks of gestation <input type="radio"/> P07.24 25 weeks of gestation <input type="radio"/> P07.25 26 weeks of gestation <input type="radio"/> P07.26 27 weeks of gestation <input type="radio"/> P07.31 28 weeks of gestation <input type="radio"/> P07.32 29 weeks of gestation <input type="radio"/> P07.33 30 weeks of gestation <input type="radio"/> P07.34 31 weeks of gestation <input type="radio"/> P07.35 32 weeks of gestation <input type="radio"/> P07.36 33 weeks of gestation <input type="radio"/> P07.37 34 weeks of gestation <input type="radio"/> P07.38 35 weeks of gestation <input type="radio"/> P07.39 36 weeks of gestation <input type="radio"/> 770.7 Chronic respiratory disease arising in the perinatal period (CLD) <input type="radio"/> 748.3 Congenital abnormality of respiratory system <input type="radio"/> Other: _____	Patient's gestational age: ____ weeks ____ days Birth weight: ____ lb/kg ____ oz Current weight: ____ lb/kg ____ oz Multiple births? <input type="radio"/> Yes <input type="radio"/> No Names of sibling RSV candidates (submit separate enrollment forms): _____ Chronic lung disease (CLD/BPD) and <24 months <input type="radio"/> Continuous oxygen (date: / / ) <input type="radio"/> Diuretics (date: / / ) chronological age AND treated for CLD within 6 months <input type="radio"/> Corticosteroids (date: / / ) <input type="radio"/> Bronchodilator (date: / / ) at start of RSV season AND (check all that apply): _____ Congenital heart disease (CHD) and <24 months <input type="radio"/> Cyanotic heart disease <input type="radio"/> Surgery to correct CHD <input type="radio"/> Medications to control CHD: chronologically age at start of season and <input type="radio"/> Acyanotic heart disease Date: / / hemodynamically significant (check all that apply): <input type="radio"/> Moderate/severe pulmonary hypertension Start date: / / <input type="radio"/> Compromised handling of secretions due to significant abnormalities of airway/neuromuscular condition and <12 months at start of RSV season <input type="radio"/> Prematurity gestational age of ≤ 28 weeks, 6 days and less than 12 months at the start of season <input type="radio"/> Prematurity gestational age of 29 weeks, 0 days to 31 weeks, 6 days AND less than 6 months at the start of season <input type="radio"/> Prematurity gestational age of 32 weeks, 0 days to 34 weeks, 6 days with the following risk factor(s) AND less than 3 months at the start of season: <input type="radio"/> Siblings < 5 years old living in the same household. Name: _____ DOB: / / <input type="radio"/> Childcare attendance with 2 or more unrelated children > 4 hours per week. Daycare name: _____ Start date: / / NICU history? <input type="radio"/> Yes <input type="radio"/> No If yes, NICU name: _____ Was this season's first Synagis dose given in the NICU? <input type="radio"/> Yes <input type="radio"/> No If yes, dates: / / Please include NICU summary. Allergies: _____ Other medical history and/or risk factors: _____ Expected date of first/next injection: / / Injection(s) already given? <input type="radio"/> Yes <input type="radio"/> No If yes, date(s): / / . / / Pharmacy to coordinate home health nurse visit for injection? <input type="radio"/> Yes <input type="radio"/> No Agency of choice: _____

5. PRESCRIPTION INFORMATION				
Medication	Dose/Strength	Directions	Quantity	Refills
<input type="radio"/> Synagis™ and ancillary supplies*	<input type="radio"/> 50 mg vials <input type="radio"/> 100 mg vials	<input type="radio"/> Inject 15 mg/kg IM once a month. <input type="radio"/> Other: _____	<input type="radio"/> QS 90 days <input type="radio"/> QS 30 days	
<input type="radio"/> Epinephrine and ancillary supplies*	1:1000 amp	<input type="radio"/> Inject 0.01 mg/kg SQ as directed for anaphylaxis. <input type="radio"/> Other: _____		
*Please list necessary ancillary supplies: _____				
<input type="radio"/> Parent or guardian has been counseled on Synagis therapy and Wellpartner may contact parent or guardian				

6. PRESCRIBER SIGNATURE	
X _____ / /	X _____ / /
DISPENSE AS WRITTEN	PRODUCT SUBSTITUTION PERMITTED
DATE	DATE

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address or telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.